floxuridine has been researched along with Angiogenesis, Pathologic in 8 studies
Floxuridine: An antineoplastic antimetabolite that is metabolized to fluorouracil when administered by rapid injection; when administered by slow, continuous, intra-arterial infusion, it is converted to floxuridine monophosphate. It has been used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
floxuridine : A pyrimidine 2'-deoxyribonucleoside compound having 5-fluorouracil as the nucleobase; used to treat hepatic metastases of gastrointestinal adenocarcinomas and for palliation in malignant neoplasms of the liver and gastrointestinal tract.
| Excerpt | Relevance | Reference |
|---|---|---|
| "This study utilized the imaging data of primary liver cancer (PLC) treated with floxuridine (FUDR) and bevacizumab to test the hypothesis that dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) parameters correlate with tissue hypoxia markers and treatment outcome." | 5.15 | Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response. ( Allen, PJ; Bamboat, Z; D'Angelica, MI; DeMatteo, RP; Fong, Y; Gönen, M; Gultekin, DH; Haviland, D; Jarnagin, WR; Kemeny, N; Schwartz, LH; Shia, J; Yopp, AC, 2011) |
| " Using a murine dorsal air sac (DAS) assay, we have previously shown that UFT and its metabolites, gamma-hydroxybutyric acid (GHB) and 5-fluorouracil (5-FU), inhibited the angiogenesis induced by murine renal cell carcinoma." | 3.71 | gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor. ( Aoyagi, K; Basaki, Y; Chikahisa, L; Hashimoto, A; Miyadera, K; Okabe, S; Wierzba, K; Yamada, Y; Yonekura, K, 2001) |
| "PD-ECGF/TP (10 ng/ml) and ovarian cancer cyst fluids (2% in medium, v/v) stimulated the production of microvessels." | 1.30 | Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: implications for the treatment of ovarian cancer. ( Collins, WP; Farzaneh, F; Hata, K; Miyazaki, K; Stevenson, DP, 1998) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (12.50) | 18.7374 |
| 1990's | 3 (37.50) | 18.2507 |
| 2000's | 3 (37.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yopp, AC | 1 |
| Schwartz, LH | 1 |
| Kemeny, N | 1 |
| Gultekin, DH | 1 |
| Gönen, M | 1 |
| Bamboat, Z | 1 |
| Shia, J | 1 |
| Haviland, D | 1 |
| D'Angelica, MI | 1 |
| Fong, Y | 1 |
| DeMatteo, RP | 1 |
| Allen, PJ | 1 |
| Jarnagin, WR | 1 |
| Kim, R | 1 |
| Murakami, S | 1 |
| Toge, T | 1 |
| Arisawa, Y | 1 |
| Sutanto-Ward, E | 1 |
| Fortunato, L | 1 |
| Sigurdson, ER | 1 |
| Stevenson, DP | 1 |
| Collins, WP | 1 |
| Farzaneh, F | 1 |
| Hata, K | 1 |
| Miyazaki, K | 1 |
| Yonekura, K | 2 |
| Basaki, Y | 2 |
| Chikahisa, L | 2 |
| Okabe, S | 2 |
| Hashimoto, A | 2 |
| Miyadera, K | 2 |
| Wierzba, K | 2 |
| Yamada, Y | 2 |
| Marchetti, S | 1 |
| Chazal, M | 1 |
| Dubreuil, A | 1 |
| Fischel, JL | 1 |
| Etienne, MC | 1 |
| Milano, G | 1 |
| Aoyagi, K | 1 |
| Terebelo, HR | 1 |
| Van Nostrand, D | 1 |
1 trial available for floxuridine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Antiangiogenic therapy for primary liver cancer: correlation of changes in dynamic contrast-enhanced magnetic resonance imaging with tissue hypoxia markers and clinical response.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antibodies, Monoclonal, Humanized; Antigens, Neopl | 2011 |
7 other studies available for floxuridine and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Effects of introduction of dThdPase cDNA on sensitivity to 5'-deoxy-5-fluorouridine and tumor angiogenesis.
Topics: Breast Neoplasms; Cell Line; Cell Line, Tumor; Cell Survival; DNA, Complementary; Dose-Response Rela | 2003 |
Hepatic artery dexamethasone infusion inhibits colorectal hepatic metastases: a regional antiangiogenic therapy.
Topics: Adenocarcinoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Capillaries; Cell Line; Che | 1995 |
Thymidine phosphorylase activity and prodrug effects in a three-dimensional model of angiogenesis: implications for the treatment of ovarian cancer.
Topics: Adult; Animals; Antineoplastic Agents; Female; Floxuridine; Humans; Isomerism; Microcirculation; Neo | 1998 |
UFT and its metabolites inhibit the angiogenesis induced by murine renal cell carcinoma, as determined by a dorsal air sac assay in mice.
Topics: 4-Butyrolactone; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Renal Cell; Cel | 1999 |
Impact of thymidine phosphorylase surexpression on fluoropyrimidine activity and on tumour angiogenesis.
Topics: Animals; Antimetabolites, Antineoplastic; Colonic Neoplasms; Drug Resistance, Neoplasm; Floxuridine; | 2001 |
gamma-Hydroxybutyric acid and 5-fluorouracil, metabolites of UFT, inhibit the angiogenesis induced by vascular endothelial growth factor.
Topics: Angiogenesis Inhibitors; Animals; Antimetabolites, Antineoplastic; Breast Neoplasms; Carcinoma; Carc | 2001 |
Systemic toxicity from arteriovenous shunting of hepatic artery infusion chemotherapy.
Topics: Arteriovenous Fistula; Female; Floxuridine; Hepatic Artery; Humans; Infusions, Intra-Arterial; Liver | 1985 |